Cloaking

Human & Animal Cell Plasma or EV Membranes

Clinically aligned solutions using plasma or EV membranes from human and mammalian cells. These cloaks offer proven immune evasion, extended circulation, and tissue-specific targeting, making them highly suitable for therapeutic applications, including RNA delivery, protein therapeutics, and nanoparticle delivery.

Milk EV Membranes

Abundant, food-grade extracellular vesicles isolated from milk offer a safe, scalable, and cost-effective platform. Ideal for oral delivery, nutraceuticals, and cosmeceuticals, milk EV membranes provide a natural, consumer-friendly route to therapeutic and wellness applications.

Plant & Algal Cell or EV Membranes

Innovative cloaks derived from edible plants and algae, enabling sustainable, inexpensive, and safe delivery solutions. With potential in oral/GI delivery, immune modulation, and functional foods, plant and algal EV membranes open new opportunities for both therapeutic and consumer health markets.

Hybrid and functionalised cloaks combine the natural advantages of biological membranes with customisable features, such as enhanced stability, targeted delivery, or immune modulation, to maximise the performance of your therapeutic cargo. Beyond natural cloaks, we engineer advanced delivery systems with added functionality:

Hybrid systems: combining biological membranes with liposomes, artificial lipid bilayers, or multi-membrane fusions to achieve stability, tunability, and combined benefits.

Surface modification: functionalising cloaks with antibodies, peptides, aptamers, glycans, or polymers for precision targeting, stealth properties, or immune modulation.

Custom engineering: designing bespoke cloaks for client-specific therapeutic goals (examples – BBB crossing, tumour targeting, immunotherapy).

We bridge discovery research with clinical application through a complete development pathway covering a broad cargo spectrum, adapted QC assays, preclinical validation and scalability.

Cargo spectrum: mRNA (CRISPR, TALENs, base editors, prime editors), plasmid DNA (CRISPR, TALEN, viral vectors), siRNA/shRNA, protein therapeutics (Cas nucleases, TALEN proteins, recombinant editors), peptides, small molecules, and nanoparticles.

Quality control: sterility, endotoxin, purity, encapsulation efficiency, stability, release kinetics, and functional validation.

Preclinical validation: uptake, biodistribution, and efficacy testing in disease-relevant models.

Scalable workflows: small discovery batches → preclinical lots → GMP-compatible production, ensuring reproducibility and regulatory alignment.